Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.
Laurent Pharmaceuticals Inc.
10 enregistrements totalisant 18,555,702.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $18,555,702 | 10 enregistrements |
Enregistrements
The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patients, and has a component allowing the transition to a new Phase 2 clinical development in mi...
Formulation scale-up & preclinical proof-of-principle in multiple animal models of rare diseases.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.